Literature DB >> 23095342

A real-life study on acquired skills from using an adrenaline autoinjector.

Erdem Topal1, Arzu Bakirtas, Ozlem Yilmaz, Ilbilge Hacer Ertoy, Mustafa Arga, Mehmet Sadik Demirsoy, Ipek Turktas.   

Abstract

BACKGROUND: Training programs performed by allergists have increased the ability of patients' recognition and management of anaphylaxis. We aim to investigate the permanence of effect of an anaphylaxis training program and to determine the factors affecting it beyond training given by allergists.
METHODS: Children and/or their caregivers who had been prescribed an adrenaline autoinjector at least 1 year before were invited to take part in the study. The knowledge about anaphylaxis was assessed using a questionnaire and the skills were practically tested.
RESULTS: Sixty-four (50 caregivers/14 children >12 years of age) of 80 patients who accepted the invitation were included in the study. Fifty-nine patients obtained the autoinjector after initial prescription. Among them, 42 (71%) still had the device at the time of the study. The most common reason for not having the autoinjector was no longer feeling it was necessary (54.6%). Of the cases, 39.4% were competent in autoinjector use. There was a significant relation between adrenaline autoinjector competency and regular allergy visits (p = 0.010), believing that it is necessary (p = 0.04), having an adrenaline autoinjector (p = 0.003), and previous history of severe anaphylaxis (p = 0.010). Autoinjector competency score decreased as time elapsed from the last visit (rho = -0.382; p = 0.002) and the first instruction (rho = -0.317; p = 0.01). Regular visits (p = 0.009) and history of severe anaphylaxis (p = 0.007) were found as independent factors having an effect on adrenaline autoinjector competency.
CONCLUSIONS: Training of patients/caregivers by allergists does not guarantee the permanence of acquired skills on anaphylaxis in the long run. Regular follow-up visits should be fostered.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23095342     DOI: 10.1159/000341367

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  5 in total

1.  How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients.

Authors:  Erminia Ridolo; Marcello Montagni; Laura Bonzano; Eleonora Savi; Silvia Peveri; Maria Teresa Costantino; Mariangiola Crivellaro; Giuseppina Manzotti; Carlo Lombardi; Marco Caminati; Cristoforo Incorvaia; Gianenrico Senna
Journal:  Intern Emerg Med       Date:  2015-05-20       Impact factor: 3.397

2.  Demonstration of epinephrine autoinjectors (EpiPen and Anapen) by pharmacists in a randomised, simulated patient assessment: acceptable, but room for improvement.

Authors:  Sandra M Salter; Richard Loh; Frank M Sanfilippo; Rhonda M Clifford
Journal:  Allergy Asthma Clin Immunol       Date:  2014-09-19       Impact factor: 3.406

3.  International consensus on (ICON) anaphylaxis.

Authors:  F Estelle R Simons; Ledit Rf Ardusso; M Beatrice Bilò; Victoria Cardona; Motohiro Ebisawa; Yehia M El-Gamal; Phil Lieberman; Richard F Lockey; Antonella Muraro; Graham Roberts; Mario Sanchez-Borges; Aziz Sheikh; Lynette P Shek; Dana V Wallace; Margitta Worm
Journal:  World Allergy Organ J       Date:  2014-05-30       Impact factor: 4.084

4.  Comparison of practical application steps of the previously used adrenaline auto injector in Turkey (EpiPen) and the currently available adrenaline auto injector (Penepin): a multi-center study.

Authors:  Erdem Topal; Hacer İlbilge Ertoy Karagöl; Özlem Yılmaz; Mustafa Arga; Burcu Köksal; Özlem Özbek Yılmaz; Hülya Anıl; Koray Harmancı; Şeyhan Kutluğ; Fadıl Öztürk; Hasan Cem Razi; İpek Türktaş; Mehmet Sadık Demirsoy; Arzu Bakırtaş
Journal:  Turk Pediatri Ars       Date:  2018-09-01

Review 5.  Comprehensive Approach: Current Status on Patient Education in Atopic Dermatitis and Other Allergic Diseases.

Authors:  Stephan Traidl; Claudia Lang; Peter Schmid-Grendelmeier; Thomas Werfel; Annice Heratizadeh
Journal:  Handb Exp Pharmacol       Date:  2022
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.